Osteopontin as a Biomarker in Pancreatitis

Pancreatitis Clinical Trial

— PtitStudien  

Official title:

Osteopontin and Other Potential Biomarkers and Factors Important for Prognosis in Pancreatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05882500
• Other study ID #: PtitStudien
• Status: Completed
• Start date: March 3, 2011
• Est. completion date: January 31, 2023

Study information

• Verified date: May 2023
• Source: Linkoeping University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In the early phase of pancreatits, factors that can give information about the development of severety are still lacking. In this study patients will be included prospectively upon the diagnosis of pancreatits and clinical as well as labarotory and radiological factors will be sampled. The aim is do identifiy factors that may aid in the risk stratification for development of different severity grades of pancreatitis.

Description:

In the early phase of pancreatits, factors that can give information about the development of severety are still lacking. In this study patients will be included prospectively upon the diagnosis of pancreatits and clinical as well as labarotory and radiological factors will be sampled. The aim is do identifiy factors that may aid in the risk stratification for development of different severity grades of pancreatitis.

Patients admitted and diagnosed with pancreatitis (according to the Atlanta criteria) will have serial testing of se-osteopontin in addiation to rutine blood work. Computet tomograpy and chest x-ray are mandatory as is blood culture.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 103
• Est. completion date: January 31, 2023
• Est. primary completion date: October 19, 2016
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of pancreatitis

Exclusion Criteria:

• Pregnancy, lactation, unable to understand the study

Related Conditions & MeSH terms

• Pancreatitis

Intervention

Other:
• No intervention, observation

Locations

Country	Name	City	State
Sweden	Linkoping University Hospital	Linköping

Sponsors (1)

Lead Sponsor	Collaborator
Linkoeping University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Se-osteopontin	Se-osteopontin will be measured at admission and on day 2 and 3 of hospital stay. The change over time will be correlated to severety of pancreatitis as classified in the current Atlanta classification.	Within 3 days from diagnosis